Disease

Osteoarthritis

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 3 TRIAL

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

ClinicalTrials.gov

This is a recruiting Phase 3 trial registration with no results posted; the study design and primary endpoints are defined but outcomes remain unreported.

PreliminaryEli Lilly and Company Overweight Or Obesity Osteoarthritis

Reported

Planned enrollment900

Study phasePhase 3

Primary endpoint 1Percent change from baseline in body weight…

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

ClinicalTrials.gov

This is a registry record for a Phase 3 trial still recruiting; no results are reported, making evidence assessment impossible at this stage.

PreliminaryEli Lilly and Company Orforglipron NCT07153471

Reported

Estimated enrollment800

Study phasePhase 3

Primary outcome measureChange from Baseline in WOMAC Pain Subscale…